Results 141 to 150 of about 5,762,549 (184)
Expert Opinion on Therapeutic Targets, 2022 Tenosynovial giant cell tumor (TGCT) is a mono-articular, benign or locally aggressive and often debilitating neoplasm. Systemic therapies are becoming part of the multimodal armamentarium when surgery alone will not confer improvements. Since TGCT is characterized by colony-stimulating factor-1 (CSF1) rearrangements, the most studied molecular pathway
Hans J. Gelderblom +2 more
exaly +5 more sources
Journal of Surgical Oncology, 2023 AbstractTenosynovial giant cell tumor (TGCT) is a rare, benign, locally aggressive synovial based neoplastic process that can result in functional debilitation and end‐stage arthrtitis. Although surgical resection is the primary treatment modality, novel systemic therapies are emerging as part of the multimodal armamentarium for patients with ...
Geert Spierenburg, Nicholas M Bernthal
exaly +3 more sources
ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)
Future Oncology, 2020 Pexidartinib is the first approved medication in the USA for people with tenosynovial giant cell tumor (TGCT). The drug was approved based on the ENLIVEN study, which looked at pexidartinib (brand name, Turalio™), a medication taken by mouth (orally) for people with TGCT (also known as giant cell tumor of the tendon sheath [GCTTS] and pigmented ...
William D Tap
exaly +3 more sources
One-Stage Synovectomies Result in Improved Short-Term Outcomes Compared to Two-Stage Synovectomies of Diffuse-Type Tenosynovial Giant Cell Tumor (D-TGCT) of the Knee: A Multicenter, Retrospective, Cohort Study [PDF]
Cancers, 2023 Diffuse-type tenosynovial giant cell tumors’ (D-TGCTs) intra- and extra-articular expansion about the knee often necessitates an anterior and posterior surgical approach to facilitate an extensive synovectomy. There is no consensus on whether two-sided synovectomies should be performed in one or two stages.
Hans J. Gelderblom +2 more
exaly +8 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Clinical Oncology, 2023
e18792 Background: In August 2019, pexidartinib became the first and only systemic therapy approved in the US for the treatment of symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
Feng Lin +6 more
openaire +1 more source
e18792 Background: In August 2019, pexidartinib became the first and only systemic therapy approved in the US for the treatment of symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
Feng Lin +6 more
openaire +1 more source
Journal of Clinical Oncology, 2023
11559 Background: TGCT is a rare type of locally aggressive neoplasm that is mainly caused by overexpression of colony-stimulating factor 1 (CSF1) gene. Pimicotinib is an oral, highly potent, and selective small-molecule antagonist of CSF-1R with minimum inhibition of c-Kit and PDGFR, and has been granted Breakthrough Therapy Designation for TGCT by ...
Lu Yao +18 more
openaire +1 more source
11559 Background: TGCT is a rare type of locally aggressive neoplasm that is mainly caused by overexpression of colony-stimulating factor 1 (CSF1) gene. Pimicotinib is an oral, highly potent, and selective small-molecule antagonist of CSF-1R with minimum inhibition of c-Kit and PDGFR, and has been granted Breakthrough Therapy Designation for TGCT by ...
Lu Yao +18 more
openaire +1 more source
Emerging therapeutics in the management of tenosynovial giant cell tumor (TGCT)
Expert Review of Anticancer TherapyTenosynovial giant cell tumors (TGCTs) are locally aggressive mesenchymal neoplasms that often occur in younger patients and cause long-term disability. Surgical management remains the standard of care, but with high risks of surgical morbidity, systemic treatment options are important to consider, particularly in diffuse disease.
Rashmi Chugh, Victoria Wytiaz
exaly +3 more sources